Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gannet BioChem Acquires Laysan Bio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Gannet BioChem Acquires Laysan Bio

Strengthens its capabilities across activated polymer technologies, including PEG reagents and bioconjugation.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Gannet BioChem, a specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, has acquired Laysan Bio, a life sciences company based in Arab, Alabama.

The acquisition strengthens Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation while enhancing its ability to support partners from early development through GMP manufacturing.

The acquisition also supports Gannet BioChem’s broader strategy to invest in specialized technologies and talent that enable innovation across activated polymers and bioconjugation, while maintaining a strong focus on quality, compliance, and long-term customer partnership.

Founded nearly two decades ago, Laysan Bio is a supplier of cataloged, custom, and compliant activated polymer reagents to academic, biotechnology, and pharmaceutical organizations. The company’s technical expertise, quality systems, and program support capabilities complement Gannet BioChem’s growing platform and enhance its ability to serve a broad range of advanced therapeutic, drug delivery and now medical device programs.

“This acquisition meaningfully expands our technical depth and manufacturing flexibility across activated polymers and bioconjugation,” said Nicholas Shackley, CEO of Gannet BioChem. “Laysan Bio’s experience, talent, and customer relationships align closely with Gannet BioChem’s mission. Together, we are building a more comprehensive platform to support partners from discovery through commercial manufacturing.”

“Joining Gannet BioChem marks an exciting next chapter for our team and our customers,” said Jon McKannan, President of Laysan Bio. “This combination creates new opportunities to scale our capabilities, broaden our offerings, and further accelerate the programs we’ve helped advance over many years.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics